Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

Chitosan-Based Multifunctional Platforms for Local Delivery of Therapeutics.

Hong SC, Yoo SY, Kim H, Lee J.

Mar Drugs. 2017 Mar 1;15(3). pii: E60. doi: 10.3390/md15030060. Review.

2.

Non-small cell lung cancer: the era of targeted therapy.

Antonoff MB, D'Cunha J.

Lung Cancer (Auckl). 2012 Jul 2;3:31-41. doi: 10.2147/LCTT.S16442. eCollection 2012. Review.

3.

KRAS mutations in the circulating free DNA (cfDNA) of non-small cell lung cancer (NSCLC) patients.

Garzón M, Villatoro S, Teixidó C, Mayo C, Martínez A, de Los Llanos Gil M, Viteri S, Morales-Espinosa D, Rosell R.

Transl Lung Cancer Res. 2016 Oct;5(5):511-516. Review.

5.

An analysis of the relationship between metastases and cachexia in lung cancer patients.

Shiono M, Huang K, Downey RJ, Consul N, Villanueva N, Beck K, Fenn K, Dietz D, Yamaguchi T, Kato S, Divgi C, Kalinsky K, Wei Y, Zhang Y, Borczuk AC, Inoue A, Halmos B, Acharyya S.

Cancer Med. 2016 Sep;5(9):2641-8. doi: 10.1002/cam4.841. Epub 2016 Aug 3.

6.

Cutaneous metastasis as an initial presentation of lung adenocarcinoma with KRAS mutation: a case report and literature review.

Liao H, Wu S, Karbowitz SR, Morgenstern N, Rose DR.

Stem Cell Investig. 2014 Mar 5;1:6. doi: 10.3978/j.issn.2306-9759.2014.03.04. eCollection 2014.

7.

IL-8 signaling is involved in resistance of lung carcinoma cells to erlotinib.

Fernando RI, Hamilton DH, Dominguez C, David JM, McCampbell KK, Palena C.

Oncotarget. 2016 Jul 5;7(27):42031-42044. doi: 10.18632/oncotarget.9662.

8.

The prevalence and prognostic significance of KRAS mutation subtypes in lung adenocarcinomas from Chinese populations.

Zheng D, Wang R, Zhang Y, Pan Y, Cheng X, Cheng C, Zheng S, Li H, Gong R, Li Y, Shen X, Sun Y, Chen H.

Onco Targets Ther. 2016 Feb 22;9:833-43. doi: 10.2147/OTT.S96834. eCollection 2016.

9.

Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation.

Vigneswaran J, Tan YH, Murgu SD, Won BM, Patton KA, Villaflor VM, Hoffman PC, Hensing T, Hogarth DK, Malik R, MacMahon H, Mueller J, Simon CA, Vigneswaran WT, Wigfield CH, Ferguson MK, Husain AN, Vokes EE, Salgia R.

Oncotarget. 2016 Apr 5;7(14):18876-86. doi: 10.18632/oncotarget.7739.

10.

Genetics and biology of pancreatic ductal adenocarcinoma.

Ying H, Dey P, Yao W, Kimmelman AC, Draetta GF, Maitra A, DePinho RA.

Genes Dev. 2016 Feb 15;30(4):355-85. doi: 10.1101/gad.275776.115. Review.

11.

Drug discovery in ophthalmology: past success, present challenges, and future opportunities.

Gower NJ, Barry RJ, Edmunds MR, Titcomb LC, Denniston AK.

BMC Ophthalmol. 2016 Jan 16;16:11. doi: 10.1186/s12886-016-0188-2. Review.

12.

Elderly male smokers with right lung tumors are viable candidates for KRAS mutation screening.

Yang Y, Shi C, Sun H, Yin W, Zhou X, Zhang L, Jiang G.

Sci Rep. 2016 Jan 7;6:18566. doi: 10.1038/srep18566.

13.

Glycoproteomic Approach Identifies KRAS as a Positive Regulator of CREG1 in Non-small Cell Lung Cancer Cells.

Clark DJ, Mei Y, Sun S, Zhang H, Yang AJ, Mao L.

Theranostics. 2016 Jan 1;6(1):65-77. doi: 10.7150/thno.12350. eCollection 2016.

14.

KRAS mutant lung cancer: progress thus far on an elusive therapeutic target.

Bhattacharya S, Socinski MA, Burns TF.

Clin Transl Med. 2015 Dec;4(1):35. doi: 10.1186/s40169-015-0075-0. Epub 2015 Dec 14.

15.

Determination of EGFR and KRAS mutational status in Greek non-small-cell lung cancer patients.

Papadopoulou E, Tsoulos N, Tsirigoti A, Apessos A, Agiannitopoulos K, Metaxa-Mariatou V, Zarogoulidis K, Zarogoulidis P, Kasarakis D, Kakolyris S, Dahabreh J, Vlastos F, Zoublios C, Rapti A, Papageorgiou NG, Veldekis D, Gaga M, Aravantinos G, Karavasilis V, Karagiannidis N, Nasioulas G.

Oncol Lett. 2015 Oct;10(4):2176-2184. Epub 2015 Aug 12.

16.

Decreased pretreatment serum cholesterol level is related with poor prognosis in resectable non-small cell lung cancer.

Li JR, Zhang Y, Zheng JL.

Int J Clin Exp Pathol. 2015 Sep 1;8(9):11877-83. eCollection 2015.

17.

Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.

Brady AK, McNeill JD, Judy B, Bauml J, Evans TL, Cohen RB, Langer C, Vachani A, Aggarwal C.

Oncotarget. 2015 Oct 6;6(30):30287-94. doi: 10.18632/oncotarget.4711.

18.

Comprehensive Molecular Analysis of NSCLC; Clinicopathological Associations.

Chatziandreou I, Tsioli P, Sakellariou S, Mourkioti I, Giannopoulou I, Levidou G, Korkolopoulou P, Patsouris E, Saetta AA.

PLoS One. 2015 Jul 24;10(7):e0133859. doi: 10.1371/journal.pone.0133859. eCollection 2015.

19.

Inhibition of class IA PI3K enzymes in non-small cell lung cancer cells uncovers functional compensation among isoforms.

Stamatkin C, Ratermann KL, Overley CW, Black EP.

Cancer Biol Ther. 2015;16(9):1341-52. doi: 10.1080/15384047.2015.1070986. Epub 2015 Jul 15.

20.

Nucleic Acid Aptamers: An Emerging Tool for Biotechnology and Biomedical Sensing.

Ku TH, Zhang T, Luo H, Yen TM, Chen PW, Han Y, Lo YH.

Sensors (Basel). 2015 Jul 6;15(7):16281-313. doi: 10.3390/s150716281. Review.

Supplemental Content

Support Center